
The utility of interferon-gamma release assays (IGRAs) for patients
Tuberculosis (TB) remains one of the world’s deadliest infectious diseases. For patients on immunosuppressive therapies, screening is critical — but also complex. Fortunately, innovations in testing offer a faster, more accurate path forward.
Join rheumatologist Dr. Shereen Mahmood as she explores TB testing strategies for immunocompromised patients and explains why interferon gamma release assays (IGRAs) like QuantiFERON-TB Gold Plus are recommended for use in patients on biologics.